Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;81(3):452-482.
doi: 10.1016/j.jinf.2020.06.015. Epub 2020 Jun 12.

Elevated nucleoprotein-induced interferon-γ release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay

Steven Thijsen  1 , Michiel Heron  1 , Hendrik Gremmels  1 , Robert van der Kieft  1 , Chantal Reusken  2 , Kristin Kremer  2 , Gijs Limonard  3 , Ailko Bossink  3
Affiliations
Comment

Elevated nucleoprotein-induced interferon-γ release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay

Steven Thijsen et al. J Infect. 2020 Sep.
No abstract available

Keywords: Covid-19; ELISpot; Interferon-gamma release assay; Sars-cov-2; T-cell response.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interests none

Figures

Fig 1
Fig. 1
SARS-CoV-2 ELISpot mosaic surface protein (a) and nucleoprotein (b) IFN-γ spot forming cells (SFC) in relation to days post onset of symptoms. SARS-CoV-2 specific IgG antibody response in COVID-19 patients versus days post onset of symptoms (c). Open and closed circles represent COVID-19 patients from the ICU and the pulmonary ward, respectively (a–c). The red oval encloses patients which seem to have a delayed or reduced T-cell response (b). Correlation between T-cell reactivity (SFC) against the SARS-CoV-2 mosaic surface protein (d) and the SARS-CoV-2 nucleoprotein (e) and concomittant SARS-CoV-2 antibody responses (IgA open symbols, IgG closed symbols) in COVID-19 patients (black symbols) and healthy controls (green symbols). The broken line represents the cut-off of the SARS-CoV-2 antibody ELISA. Fig. 1f depicts the ROC analyses of the SARS-CoV-2 nucleoprotein ELISpot results in COVID-19 patients at >7 days, >14 days and >21 days post the onset of symptoms versus healthy controls.
See this image and copyright information in PMC

Comment on

References

    1. Demey B., Daher N., François C., Lanoix J.-.P., Duverlie G., Castelain S. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. J Infect [Internet] 2020 May 7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204722/ cited 2020 Jun 2]; Available from: - PMC - PubMed
    1. Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H. Clinical and immunological features of severe and moderate coronavirus disease. J Clin Invest. 2019;130(5):2620–2629. 2020 01. - PMC - PubMed
    1. Xu B., Fan C.-.Y., Wang A.-.L., Zou Y.-.L., Yu Y.-.H., He C. Suppressed T cell-mediated immunity in patients with COVID-19: a clinical retrospective study in Wuhan. China. J Infect. 2020 Apr 18 - PMC - PubMed
    1. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. Dysregulation of immune response in patients with COVID-19 in Wuhan. China. Clin Infect Dis. 2020 Mar 12 - PMC - PubMed
    1. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell [Internet] 2020 May 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7237901/ cited 2020 Jun 2]; Available from: - PMC - PubMed